Selenium Attenuates Radiation Colitis by Regulating cGAS‐STING Signaling
Source abstract
Abstract
Abstract Radiation colitis is one of the most common complications in patients undergoing pelvic radiotherapy and there is no effective treatment in the clinic. Therefore, searching for effective agents for the treatment of radiation colitis is urgently needed. Herein, it is found that the essential element selenium (Se) is protective against radiation colitis through inhibiting X‐ray‐induced apoptosis, cell cycle arrest, and inflammation with the involvement of balancing the generation of reactive oxygen species after the irradiation. Mechanistically, Se, especially for selenium nanoparticles (SeNPs), induced selenoprotein expression and then functioned to effectively restrain DNA damage response, which reduced X‐ray‐induced intestinal injury. Additionally, SeNPs treatment also restrained the cyclic GMP‐AMP synthas (cGAS)‐ stimulator of interferon genes (STING)‐TBK1‐IRF3 signaling pathway cascade, thereby blocking the transcription of inflammatory cytokine gene, IL‐6 and TNF‐α, and thus alleviating inflammation. Moreover, inducing selenoprotein expression, such as GPX4, with SeNPs in vivo can regulate intestinal microenvironment immunity and gut microbiota to attenuate radiation‐induced colitis by inhibiting oxidative stress and maintaining microenvironment immunity homeostasis. Together, these results unravel a previously unidentified modulation role that SeNPs restrained radiation colitis with the involvement of inducing selenoprotein expression but suppressing cGAS‐STING‐TBK1‐IRF3 cascade.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Inflammasome and immune disorders · Ferroptosis and cancer prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiation Oncology of Puning People's Hospital Department of Chemistry of Jinan University State Key Laboratory of Bioactive Molecules and Druggalibility Assessment MOE Key Laboratory of Tumor Molecular Biology Jinan University Guangdong China
Funding
National Key Research and Development Program of China · National Science Fund for Distinguished Young Scholars · National Natural Science Foundation of China
References (57)
Show source-provided references
1. 10.1200/JCO.22.0276410.1200/JCO.22.02764 ↗
2. 10.1001/jamaoncol.2022.759210.1001/jamaoncol.2022.7592 ↗
3. 10.1002/pro6.121710.1002/pro6.1217 ↗
4. 10.1017/S002966511800010110.1017/S0029665118000101 ↗
5. 10.1002/pro6.114110.1002/pro6.1141 ↗
6. 10.3322/caac.2168910.3322/caac.21689 ↗
7. 10.3322/caac.2172710.3322/caac.21727 ↗
8. 10.1053/j.gastro.2022.01.02310.1053/j.gastro.2022.01.023 ↗
9. 10.1038/s41467-023-40794-w10.1038/s41467-023-40794-w ↗
10. 10.1021/acsnano.3c0887510.1021/acsnano.3c08875 ↗
11. 10.1002/advs.20230070810.1002/advs.202300708 ↗
12. 10.1038/s41467-023-44390-w10.1038/s41467-023-44390-w ↗
13. 10.1016/j.biomaterials.2020.11994010.1016/j.biomaterials.2020.119940 ↗
14. 10.1038/s41575-019-0261-410.1038/s41575-019-0261-4 ↗
15. 10.1124/pharmrev.120.00007210.1124/pharmrev.120.000072 ↗
16. 10.1080/19490976.2024.233146010.1080/19490976.2024.2331460 ↗
17. 10.1016/j.tcb.2022.11.00110.1016/j.tcb.2022.11.001 ↗
18. 10.1038/s41580-020-0244-x10.1038/s41580-020-0244-x ↗
19. 10.1038/s41418-022-01094-w10.1038/s41418-022-01094-w ↗
20. 10.1002/advs.20230727810.1002/advs.202307278 ↗
21. 10.1016/j.celrep.2019.09.05010.1016/j.celrep.2019.09.050 ↗
22. 10.1038/ni.355810.1038/ni.3558 ↗
23. 10.1126/science.aat865710.1126/science.aat8657 ↗
24. 10.1186/s12943-020-01250-110.1186/s12943-020-01250-1 ↗
25. 10.1038/s41392-020-0198-710.1038/s41392-020-0198-7 ↗
26. 10.1093/procel/pwad04410.1093/procel/pwad044 ↗
27. 10.3857/roj.2023.0034610.3857/roj.2023.00346 ↗
28. 10.1016/j.tem.2023.05.00610.1016/j.tem.2023.05.006 ↗
29. 10.1038/s12276-022-00911-z10.1038/s12276-022-00911-z ↗
30. 10.1021/acsnano.3c0457810.1021/acsnano.3c04578 ↗
31. 10.1002/advs.20230088010.1002/advs.202300880 ↗
32. 10.1002/advs.20230190210.1002/advs.202301902 ↗
33. 10.1016/S0140-6736(11)61452-910.1016/S0140-6736(11)61452-9 ↗
34. 10.1016/j.redox.2020.10151910.1016/j.redox.2020.101519 ↗
35. 10.1186/s40104-020-00531-510.1186/s40104-020-00531-5 ↗
36. 10.1016/S2468-1253(23)00011-010.1016/S2468-1253(23)00011-0 ↗
37. 10.1016/j.imbio.2024.15283910.1016/j.imbio.2024.152839 ↗
38. 10.1016/j.freeradbiomed.2022.06.23210.1016/j.freeradbiomed.2022.06.232 ↗
39. 10.1002/EXP.2023011510.1002/EXP.20230115 ↗
40. 10.1186/s12645-024-00262-610.1186/s12645-024-00262-6 ↗
41. 10.1002/advs.20200333810.1002/advs.202003338 ↗
42. 10.1002/advs.20240203910.1002/advs.202402039 ↗
43. 10.1016/j.cclet.2023.10826410.1016/j.cclet.2023.108264 ↗
44. 10.1002/advs.20230890510.1002/advs.202308905 ↗
45. 10.1016/j.ccr.2023.21531610.1016/j.ccr.2023.215316 ↗
46. 10.1038/s41423-023-00998-y10.1038/s41423-023-00998-y ↗
47. 10.1002/advs.20240084510.1002/advs.202400845 ↗
48. 10.1038/s41392-023-01452-110.1038/s41392-023-01452-1 ↗
49. 10.1038/s41575-023-00864-210.1038/s41575-023-00864-2 ↗
50. 10.1038/s41577-023-00874-w10.1038/s41577-023-00874-w ↗
51. 10.1002/advs.20220736610.1002/advs.202207366 ↗
52. 10.1002/advs.20220717010.1002/advs.202207170 ↗
53. 10.1007/s11427-022-2302-510.1007/s11427-022-2302-5 ↗
54. 10.1016/j.nantod.2020.10097510.1016/j.nantod.2020.100975 ↗
55. 10.1021/acsnano.3c0434410.1021/acsnano.3c04344 ↗
56. 10.1016/j.cej.2019.12356310.1016/j.cej.2019.123563 ↗
57. 10.1021/jacs.3c0217910.1021/jacs.3c02179 ↗